What Is Journavx? The First-in-Class Non-Opioid Pain Drug
FDA approved Journavx, or suzetrigine, in January 2025 for moderate to severe acute pain in adults, creating a non-opioid analgesic class that targets peripheral sodium-channel pain signaling.
Timeline
- January 30, 2025: FDA approved Journavx 50-milligram tablets for moderate to severe acute pain in adults.
- At approval: FDA described suzetrigine as the first medicine in a new non-opioid analgesic class.
- Clinical program: Two controlled surgical-pain trials and a broader safety study contributed evidence from 2,447 participants.
The US Food and Drug Administration approved Journavx, the brand name for suzetrigine, on January 30, 2025. Its indication is moderate to severe acute pain in adults. Acute pain is short term and often follows an injury or operation. The approval did not establish Journavx as a treatment for every chronic-pain condition or for children. [1][2]
Suzetrigine is a non-opioid sodium-channel blocker. FDA explains that it reduces pain by targeting a signaling pathway in the peripheral nervous system before pain signals reach the brain. Because it does not work through opioid receptors, it represents a different drug class, but non-opioid does not mean risk-free or appropriate for every patient. [1][2]
FDA based the approval on three studies involving 2,447 people with moderate to severe acute pain. Two randomized, double-blind trials studied pain after abdominoplasty and bunion surgery. Participants received Journavx, placebo or hydrocodone with acetaminophen for 48 hours. All groups could use ibuprofen as rescue medication if pain control was inadequate. [1][2]
In both surgical trials, FDA reported that Journavx reduced pain more than placebo using a time-weighted pain-score measure. Comparisons with hydrocodone-acetaminophen did not demonstrate superiority, which is different from proving the drugs are equivalent in every setting. A third study enrolled people with surgical and nonsurgical acute pain primarily to add safety experience. [1][2]
The FDA snapshot states that treatment begins with a 100-milligram oral dose, followed 12 hours later by 50 milligrams every 12 hours. Patients should follow the current prescribing information because food instructions, treatment duration, liver impairment and other clinical factors can affect use. The medicine is prescription only and should not be started or adjusted from a summary article. [2]
Reported common adverse reactions included itching, muscle spasms, increased creatine phosphokinase and rash. FDA also highlighted drug-interaction and food considerations involving the CYP3A pathway, and the prescribing information contains restrictions for some combinations. Pregnancy, liver function and other medicines are reasons for a clinician or pharmacist to review the full label before treatment. [1][2]
Journavx matters because it added a new mechanism for adult acute-pain management at a time of concern about opioid harms. Its role is narrower than a universal opioid replacement: the approval covers a defined indication, trial averages do not predict an individual's response, and rescue treatment was allowed in the pivotal studies. Current labeling and professional care remain the practical guides. [1][2]